Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report
The present article reports the case of a patient presenting with chronic myeloid leukemia, diagnosed during the accelerated phase (>20% blasts in peripheral blood samples and megakaryocyte agglomerates in the bone marrow). The subject was treated with first-line therapy with the tyrosine kin...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.696253/full |
| _version_ | 1818739815432060928 |
|---|---|
| author | Isabella Capodanno Elisabetta Lugli Katia Codeluppi Mariapina Faruolo Enrica Bellesia Riccardo Valli Francesco Merli |
| author_facet | Isabella Capodanno Elisabetta Lugli Katia Codeluppi Mariapina Faruolo Enrica Bellesia Riccardo Valli Francesco Merli |
| author_sort | Isabella Capodanno |
| collection | DOAJ |
| description | The present article reports the case of a patient presenting with chronic myeloid leukemia, diagnosed during the accelerated phase (>20% blasts in peripheral blood samples and megakaryocyte agglomerates in the bone marrow). The subject was treated with first-line therapy with the tyrosine kinase inhibitor nilotinib and reached complete clinical and molecular remission (according to the European Leukemia Net-ELN-criteria), which persisted over five years of treatment. Five years after discontinuation of nilotinib (ten years from diagnosis), the patient is in good clinical condition, with no traces of BCL-ABL1 at molecular evaluation (molecular response, MR5). The case is discussed in the setting of current literature, providing an overview on chronic myeloid leukemia and a discussion on treatment options available. |
| first_indexed | 2024-12-18T01:30:50Z |
| format | Article |
| id | doaj.art-7c1c13da83ea40bc9d1fa016a809822f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-18T01:30:50Z |
| publishDate | 2021-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7c1c13da83ea40bc9d1fa016a809822f2022-12-21T21:25:37ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-06-011110.3389/fonc.2021.696253696253Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case ReportIsabella Capodanno0Elisabetta Lugli1Katia Codeluppi2Mariapina Faruolo3Enrica Bellesia4Riccardo Valli5Francesco Merli6Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Struttura Complessa di Ematologia, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Struttura Complessa di Ematologia, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Struttura Complessa di Ematologia, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Struttura Complessa di Ematologia, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Laboratorio Chimico Clinico e di Endocrinologia, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Servizio di Anatomia Patologica, Reggio Emilia, ItalyAzienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Struttura Complessa di Ematologia, Reggio Emilia, ItalyThe present article reports the case of a patient presenting with chronic myeloid leukemia, diagnosed during the accelerated phase (>20% blasts in peripheral blood samples and megakaryocyte agglomerates in the bone marrow). The subject was treated with first-line therapy with the tyrosine kinase inhibitor nilotinib and reached complete clinical and molecular remission (according to the European Leukemia Net-ELN-criteria), which persisted over five years of treatment. Five years after discontinuation of nilotinib (ten years from diagnosis), the patient is in good clinical condition, with no traces of BCL-ABL1 at molecular evaluation (molecular response, MR5). The case is discussed in the setting of current literature, providing an overview on chronic myeloid leukemia and a discussion on treatment options available.https://www.frontiersin.org/articles/10.3389/fonc.2021.696253/fullnilotinibchronic myeloid leukemiatyrosine kinase inhibitoraccelerated phasetreatment free remission |
| spellingShingle | Isabella Capodanno Elisabetta Lugli Katia Codeluppi Mariapina Faruolo Enrica Bellesia Riccardo Valli Francesco Merli Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report Frontiers in Oncology nilotinib chronic myeloid leukemia tyrosine kinase inhibitor accelerated phase treatment free remission |
| title | Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report |
| title_full | Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report |
| title_fullStr | Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report |
| title_full_unstemmed | Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report |
| title_short | Accelerated Phase Chronic Myeloid Leukemia and Treatment Free Remission Maintained After Five Years of Nilotinib: A Case Report |
| title_sort | accelerated phase chronic myeloid leukemia and treatment free remission maintained after five years of nilotinib a case report |
| topic | nilotinib chronic myeloid leukemia tyrosine kinase inhibitor accelerated phase treatment free remission |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.696253/full |
| work_keys_str_mv | AT isabellacapodanno acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT elisabettalugli acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT katiacodeluppi acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT mariapinafaruolo acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT enricabellesia acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT riccardovalli acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport AT francescomerli acceleratedphasechronicmyeloidleukemiaandtreatmentfreeremissionmaintainedafterfiveyearsofnilotinibacasereport |